O	0	10	Optimizing
O	11	23	expectations
O	24	26	to
O	27	34	prevent
O	35	39	side
O	40	47	effects
O	48	51	and
O	52	59	enhance
O	60	67	quality
O	68	70	of
O	71	75	life
O	76	78	in
O	79	85	breast
O	86	92	cancer
O	93	101	patients
O	102	112	undergoing
O	113	122	endocrine
O	123	130	therapy
O	130	131	:
O	132	137	study
O	138	146	protocol
O	147	149	of
O	150	151	a
O	152	162	randomized
O	163	173	controlled
O	174	179	trial
O	179	180	.

O	181	189	Adjuvant
O	190	199	endocrine
O	200	207	therapy
O	208	211	can
O	212	219	improve
O	220	227	disease
O	227	228	-
O	228	232	free
O	233	241	survival
O	242	245	and
O	246	250	time
O	251	257	before
O	258	268	recurrence
O	269	271	in
O	272	278	breast
O	279	285	cancer
O	286	294	patients
O	294	295	.

O	296	303	However
O	303	304	,
O	305	307	it
O	308	310	is
O	311	321	associated
O	322	326	with
O	327	339	considerable
O	340	344	side
O	345	352	effects
O	353	357	that
O	358	368	negatively
O	369	375	affect
O	376	384	patients
O	384	385	'
O	386	393	quality
O	394	396	of
O	397	401	life
O	402	405	and
O	406	411	cause
O	412	415	non
O	415	416	-
O	416	425	adherence
O	425	426	.

O	427	430	The
O	431	439	recently
O	440	452	demonstrated
O	453	459	effect
O	460	462	of
O	463	473	individual
O	474	486	expectations
O	487	489	on
O	490	494	side
O	494	495	-
O	495	501	effect
O	502	513	development
O	514	515	(
O	515	521	nocebo
O	522	528	effect
O	528	529	)
O	530	538	suggests
O	539	543	that
O	544	557	psychological
O	558	565	factors
O	566	570	play
O	571	572	a
O	573	577	role
O	578	580	in
O	581	584	the
O	585	595	prevention
O	596	598	of
O	599	603	side
O	604	611	effects
O	611	612	.

O	613	616	The
O	617	620	aim
O	621	623	of
O	624	628	this
O	629	634	study
O	635	637	is
O	638	640	to
O	641	649	evaluate
B-intervention	650	659	cognitive
I-intervention	659	660	-
I-intervention	660	670	behavioral
I-intervention	671	675	side
I-intervention	675	676	-
I-intervention	676	682	effect
I-intervention	683	693	prevention
I-intervention	694	702	training
I-intervention	703	704	(
I-intervention	704	708	SEPT
I-intervention	708	709	)
O	710	713	for
O	714	720	breast
O	721	727	cancer
O	728	736	patients
O	736	737	.

O	738	742	This
O	743	750	article
O	751	760	describes
O	761	764	the
O	765	770	study
O	771	779	protocol
O	780	783	and
O	784	791	applied
O	792	800	research
O	801	808	methods
O	808	809	.

O	810	812	In
O	813	814	a
O	815	825	randomized
O	826	836	controlled
O	837	842	trial
O	842	843	,
B-total-participants	844	847	184
O	848	854	female
O	855	861	breast
O	862	868	cancer
O	869	877	patients
O	878	881	are
O	882	890	assigned
O	891	893	to
O	894	901	receive
O	902	908	either
O	909	913	SEPT
O	913	914	,
B-control	915	923	standard
I-control	924	931	medical
I-control	932	936	care
O	937	939	or
O	940	941	a
B-control	942	952	manualized
I-control	953	963	supportive
I-control	964	971	therapy
O	972	974	at
O	975	978	the
O	979	984	start
O	985	987	of
O	988	996	adjuvant
O	997	1006	endocrine
O	1007	1016	treatment
O	1016	1017	.

O	1018	1022	SEPT
O	1023	1031	consists
O	1032	1034	of
O	1035	1040	three
O	1041	1049	sessions
O	1050	1052	of
O	1053	1062	cognitive
O	1062	1063	-
O	1063	1073	behavioral
O	1074	1082	training
O	1083	1092	including
O	1093	1108	psychoeducation
O	1109	1111	to
O	1112	1119	provide
O	1120	1121	a
O	1122	1131	realistic
O	1132	1136	view
O	1137	1139	of
O	1140	1149	endocrine
O	1150	1157	therapy
O	1157	1158	,
O	1159	1170	imagination
O	1170	1171	-
O	1171	1179	training
O	1180	1182	to
O	1183	1192	integrate
O	1193	1201	positive
O	1202	1209	aspects
O	1210	1212	of
O	1213	1223	medication
O	1224	1228	into
O	1229	1234	daily
O	1235	1239	life
O	1239	1240	,
O	1241	1244	and
O	1245	1249	side
O	1249	1250	-
O	1250	1256	effect
O	1257	1267	management
O	1268	1270	to
O	1271	1278	enhance
O	1279	1291	expectations
O	1292	1297	about
O	1298	1304	coping
O	1305	1312	ability
O	1312	1313	.

B-outcome-Measure	1314	1318	Side
I-outcome-Measure	1319	1326	effects
O	1327	1332	three
O	1333	1339	months
O	1340	1345	after
O	1346	1349	the
O	1350	1355	start
O	1356	1358	of
O	1359	1368	endocrine
O	1369	1376	therapy
O	1377	1382	serve
O	1383	1385	as
O	1386	1393	primary
O	1394	1402	outcomes
O	1402	1403	.

O	1404	1413	Secondary
O	1414	1422	outcomes
O	1423	1430	include
B-outcome-Measure	1431	1438	quality
I-outcome-Measure	1439	1441	of
I-outcome-Measure	1442	1446	life
O	1446	1447	,
B-outcome-Measure	1448	1454	coping
I-outcome-Measure	1455	1462	ability
O	1463	1466	and
B-outcome-Measure	1467	1475	patients
I-outcome-Measure	1475	1476	'
I-outcome-Measure	1477	1487	medication
I-outcome-Measure	1488	1497	adherence
O	1497	1498	.

O	1499	1507	Patients
O	1507	1508	'
O	1509	1521	expectations
O	1522	1523	(
O	1523	1524	i
O	1524	1525	.
O	1525	1526	e
O	1526	1527	.
O	1527	1528	,
O	1529	1541	expectations
O	1542	1547	about
O	1548	1552	side
O	1553	1560	effects
O	1560	1561	,
O	1562	1568	coping
O	1569	1576	ability
O	1576	1577	,
O	1578	1587	treatment
O	1588	1591	and
O	1592	1599	illness
O	1599	1600	)
O	1601	1604	are
O	1605	1613	analyzed
O	1614	1616	as
O	1617	1626	mediators
O	1626	1627	.

O	1628	1631	The
O	1632	1644	optimization
O	1645	1647	of
O	1648	1660	expectations
O	1661	1666	might
O	1667	1669	be
O	1670	1671	a
O	1672	1681	potential
O	1682	1689	pathway
O	1690	1692	in
O	1693	1699	health
O	1700	1704	care
O	1705	1707	to
O	1708	1715	improve
O	1716	1724	patients
O	1724	1725	'
O	1726	1733	quality
O	1734	1736	of
O	1737	1741	life
O	1742	1748	during
O	1749	1753	long
O	1753	1754	-
O	1754	1758	term
O	1759	1769	medication
O	1770	1776	intake
O	1776	1777	.

O	1778	1781	The
O	1782	1789	results
O	1790	1794	will
O	1795	1802	provide
O	1803	1815	implications
O	1816	1819	for
O	1820	1821	a
O	1822	1830	possible
O	1831	1842	integration
O	1843	1845	of
O	1846	1854	evidence
O	1854	1855	-
O	1855	1860	based
O	1861	1871	prevention
O	1872	1880	training
O	1881	1885	into
O	1886	1894	clinical
O	1895	1903	practice
O	1903	1904	.

O	1905	1919	ClinicalTrials
O	1919	1920	.
O	1920	1923	gov
O	1923	1924	,
O	1925	1926	(
O	1926	1937	NCT01741883
O	1937	1938	)
O	1938	1939	.
